Oxygen Saturation and Perfusion Index ın Neonates at High Altitude
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04290481 |
Recruitment Status :
Completed
First Posted : March 2, 2020
Last Update Posted : March 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. This figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. Most of these defects do not need treatment or treatment is needed after infancy. Other defects are severe and usually require early treatment in the neonatal period. Critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. Critical congenital heart disease is estimated to be ~3 in 1000 live births. It is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. Even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed.
Screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease.
The American Academy of Pediatrics, the American Cardiology Foundation and the American Heart Association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia.
The reference values of peripheral perfusion (PPI) index has been established for normal newborns between 1 and 120 h of age.
Lower PPI values than 0.70 may indicate illness. Including cut-off values for PPI in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation.
We aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.
Condition or disease | Intervention/treatment |
---|---|
Critical Congenital Heart Disease High Altitude | Other: oxygen saturation and perfusion index screening |
Study Type : | Observational |
Actual Enrollment : | 501 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Oxygen Saturation and Perfusion Index Screening ın Neonates at High Altitude |
Actual Study Start Date : | June 1, 2018 |
Actual Primary Completion Date : | February 1, 2019 |
Actual Study Completion Date : | February 1, 2019 |

- Other: oxygen saturation and perfusion index screening
Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
- Establishing threshold values for critical congenital heart disease screening at high altitude [ Time Frame: Postnatal 24-48 hours ]We aim to explore whether oxygen saturation and perfusion index threshold values are different compared sea level or not.
- Establishing normal oxygen saturation and perfusion index values at high altitude [ Time Frame: Postnatal 24-48 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 48 Hours (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- The newborns delivered in Ataturk University Hospital and ≥34 weeks of gestational age were eligible for the study.
Exclusion Criteria:
- Outborn and premature babies (<34 weeks) were not included. Babies with a prenatal diagnosis of congenital heart disease were excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04290481
Turkey | |
Ataturk University Medical Faculty | |
Erzurum, Turkey, 25100 |
Responsible Party: | Kadir Şerafettin Tekgündüz, Associate Prof, Ataturk University |
ClinicalTrials.gov Identifier: | NCT04290481 |
Other Study ID Numbers: |
B.30.2.ATA.0.01.00/32 |
First Posted: | March 2, 2020 Key Record Dates |
Last Update Posted: | March 2, 2020 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Altitude Sickness Heart Diseases Cardiovascular Diseases Respiration Disorders Respiratory Tract Diseases |